Q1 2025 · 13F-HR
B Group, Inc.holdings as filed
Filed 2025-05-15 · accession 0001420506-25-001152
$116.7M
Reported value
19
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 000899104 | ADMA | ADMA BIOLOGICS INC | $46.0M | 39.4% | 2,317,542 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $20.0M | 17.2% | 262,500 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $14.5M | 12.4% | 400,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $9.8M | 8.41% | 242,500 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $5.0M | 4.28% | 1,500,000 | Common | SOLE |
| 15117K103 | CLLS | CELLECTIS S A | $4.0M | 3.46% | 3,256,501 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $2.8M | 2.37% | 472,576 | Common | SOLE |
| 82657M105 | SGHT | SIGHT SCIENCES INC | $2.0M | 1.71% | 833,600 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $1.9M | 1.64% | 200,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $1.7M | 1.50% | 1,255,556 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $1.7M | 1.47% | 47,500 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE | $1.4M | 1.17% | 15,000 | Common | SOLE |
| 90400D908 | — | ULTRAGENYX PHARMACEUTICAL IN | $1.4M | 1.17% | 37,600 | CALL | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $1.1M | 0.97% | 70,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $1.1M | 0.96% | 30,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $719,530 | 0.62% | 19,000 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $695,179 | 0.60% | 95,623 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $597,286 | 0.51% | 58,215 | Common | SOLE |
| 221015950 | — | CORVUS PHARMACEUTICALS INC | $286,200 | 0.25% | 90,000 | PUT | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.